alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>


<ARTICLE>                                            9
<MULTIPLIER>                                   1000

<S>                             <C>
<PERIOD-TYPE>                   9-Mos
<FISCAL-YEAR-END>                              DEC-31-2000
<PERIOD-START>                                 JAN-01-2000
<PERIOD-END>                                   SEP-30-2000
<CASH>                                            20,112
<INT-BEARING-DEPOSITS>                                 0
<FED-FUNDS-SOLD>                                       0
<TRADING-ASSETS>                                       0
<INVESTMENTS-HELD-FOR-SALE>                      130,867
<INVESTMENTS-CARRYING>                            42,169
<INVESTMENTS-MARKET>                              41,808
<LOANS>                                          549,033
<ALLOWANCE>                                        6,085
<TOTAL-ASSETS>                                   757,637
<DEPOSITS>                                       651,649
<SHORT-TERM>                                      26,875
<LIABILITIES-OTHER>                                6,904
<LONG-TERM>                                       13,000
<PREFERRED-MANDATORY>                                  0
<PREFERRED>                                            0
<COMMON>                                           5,397
<OTHER-SE>                                        53,812
<TOTAL-LIABILITIES-AND-EQUITY>                   757,637
<INTEREST-LOAN>                                   32,723
<INTEREST-INVEST>                                  7,850
<INTEREST-OTHER>                                     528
<INTEREST-TOTAL>                                  41,101
<INTEREST-DEPOSIT>                                16,002
<INTEREST-EXPENSE>                                17,644
<INTEREST-INCOME-NET>                             23,457
<LOAN-LOSSES>                                        750
<SECURITIES-GAINS>                                    97
<EXPENSE-OTHER>                                   15,908
<INCOME-PRETAX>                                    9,859
<INCOME-PRE-EXTRAORDINARY>                         9,859
<EXTRAORDINARY>                                        0
<CHANGES>                                              0
<NET-INCOME>                                       6,599
<EPS-BASIC>                                         1.01
<EPS-DILUTED>                                       1.01
<YIELD-ACTUAL>                                      4.45
<LOANS-NON>                                        1,113
<LOANS-PAST>                                          24
<LOANS-TROUBLED>                                       0
<LOANS-PROBLEM>                                        0
<ALLOWANCE-OPEN>                                   5,476
<CHARGE-OFFS>                                        214
<RECOVERIES>                                          73
<ALLOWANCE-CLOSE>                                  6,085
<ALLOWANCE-DOMESTIC>                               6,085
<ALLOWANCE-FOREIGN>                                    0
<ALLOWANCE-UNALLOCATED>                            2,773



</TABLE>
# C_2016402EN.01002901.xml

| 31.10.2016 | EN | Official Journal of the European Union | C 402/29 |
| --- | --- | --- | --- |

31.10.2016

EN

Official Journal of the European Union

C 402/29

---

Judgment of the General Court of 15 September 2016 — Unitec Bio v Council

(Case T-111/14) (1)

1

((Dumping - Imports of biodiesel originating in Argentina - Definitive anti-dumping duty - Action for annulment - Direct concern - Individual concern - Admissibility - Article 2(5) of Regulation (EC) No 1225/2009 - Normal value - Production costs))

(2016/C 402/31)

Language of the case: English

Parties

Parties

Applicant: Unitec Bio SA (Buenos Aires, Argentina) (represented by: J.-F. Bellis, R. Luff and G. Bathory, lawyers)

Applicant:

Defendant: Council of the European Union (represented initially by S. Boelaert and B. Driessen, and subsequently by H. Marcos Fraile, acting as Agents, and by R. Bierwagen and C. Hipp, lawyers)

Defendant:

Interveners in support of the defendant: European Commission (represented by M. França and A. Stobiecka-Kuik, acting as Agents) and European Biodiesel Board (EBB) (Brussels, Belgium) (represented by O. Prost and M.-S. Dibling, lawyers)

Interveners in support of the defendant:

Re:

Re:

Action pursuant to Article 263 TFUE for annulment of Council Implementing Regulation (EU) No 1194/2013 of 19 November 2013 imposing a definitive anti-dumping duty and collecting definitively the provisional duty imposed on imports of biodiesel originating in Argentina and Indonesia (OJ 2013 L 315, p. 2) in so far as it imposes an anti-dumping duty on the applicant.

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Annuls Articles 1 and 2 of Council Implementing Regulation (EU) No 1194/2013 of 19 November 2013 imposing a definitive anti-dumping duty and collecting definitively the provisional duty imposed on imports of biodiesel originating in Argentina and Indonesia, in so far as they concern Unitec Bio SA; |
| --- | --- |

1.

Annuls Articles 1 and 2 of Council Implementing Regulation (EU) No 1194/2013 of 19 November 2013 imposing a definitive anti-dumping duty and collecting definitively the provisional duty imposed on imports of biodiesel originating in Argentina and Indonesia, in so far as they concern Unitec Bio SA;

| 2. | Orders the Council of the European Union to bear its own costs and to pay the costs incurred by Unitec Bio; |
| --- | --- |

2.

Orders the Council of the European Union to bear its own costs and to pay the costs incurred by Unitec Bio;

| 3. | Orders the European Commission and the European Biodiesel Board (EBB) to bear their own costs. |
| --- | --- |

3.

Orders the European Commission and the European Biodiesel Board (EBB) to bear their own costs.

---

(1)  OJ C 112, 14.4.2014.

1

---
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1
<CURRENCY> U.S. DOLLARS
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          SEP-30-1998
<PERIOD-START>                             OCT-01-1997
<PERIOD-END>                               DEC-31-1997
<EXCHANGE-RATE>                                      1
<CASH>                                             428
<SECURITIES>                                         0
<RECEIVABLES>                                   42,144
<ALLOWANCES>                                         0
<INVENTORY>                                     38,035
<CURRENT-ASSETS>                                83,387
<PP&E>                                         118,586
<DEPRECIATION>                                  52,609
<TOTAL-ASSETS>                                 224,737
<CURRENT-LIABILITIES>                           55,080
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        23,395
<OTHER-SE>                                           0
<TOTAL-LIABILITY-AND-EQUITY>                   224,737
<SALES>                                         79,618
<TOTAL-REVENUES>                                79,618
<CGS>                                           61,487
<TOTAL-COSTS>                                   77,884
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               1,608
<INCOME-PRETAX>                                    126
<INCOME-TAX>                                        44
<INCOME-CONTINUING>                                 82
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                        82
<EPS-PRIMARY>                                      .01
<EPS-DILUTED>                                      .01
        

</TABLE>
----

**EXHIBIT 13.A**

 

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350,**

**AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

 

In connection with the Annual Report of Petaquilla Minerals Ltd. (the “Company”) on amended Form 20-F for the 13 months ended May 31, 2008 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Richard Fifer, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

|        |        |        |                                                                                                                                                             |
|--------|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   | 1.     |   | The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and |
|   |   |   |                                                                                                                                                        |
|   | 2.     |   | The information contained in the Report fairly presents, in all materials respects, the financial condition and results of operations of the Company.       |

 

 

|                               |        |
|-------------------------------|--------|
| /s/ Richard Fifer             |   |
| Richard Fifer                 |   |
| (principal executive officer) |   |

 

Dated:  November 25, 2008

 

 

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

----
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7473 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7473

     To ensure continued appropriations for certain Small Business 
  Administration programs during a Government shutdown in fiscal year 
                     2024, and for other purposes.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                           February 28, 2024

Mr. Schiff (for himself, Mr. Thanedar, Mrs. Foushee, and Mr. Castro of 
    Texas) introduced the following bill; which was referred to the 
                      Committee on Appropriations

_______________________________________________________________________

                                 A BILL

 
     To ensure continued appropriations for certain Small Business 
  Administration programs during a Government shutdown in fiscal year 
                     2024, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Funding Small Businesses During 
Shutdown Act''.

SEC. 2. CONTINUATION OF CERTAIN SMALL BUSINESS ADMINISTRATION PROGRAMS 
              DURING A GOVERNMENT SHUTDOWN.

    There are appropriated for fiscal year 2024, out of any money in 
the Treasury not otherwise appropriated, during any period of a lapse 
in discretionary appropriations with respect to the Small Business 
Administration during such fiscal year beginning on or after the date 
of the enactment of this section, for any 30-day period of such lapse 
(and on a pro-rated basis if such lapse is less than 30 days) to pay 
for the salaries and expenses necessary to continue servicing any loans 
made under--
            (1) $500,000 for loans made under subsection (m) of section 
        7 of the Small Business Act (15 U.S.C. 636(m));
            (2) $2,916,666,667 for loans made under subsection (a) of 
        section 7 of the Small Business Act (15 U.S.C. 636(a));
            (3) $1,250,000,000 for loans made under title V of the 
        Small Business Investment Act of 1958 (15 U.S.C. 695 et seq.); 
        and
            (4) $13,775,000 for administrative expenses to carry out 
        the loan program under subsection (m) of section 7 of the Small 
        Business Act (15 U.S.C. 636(m)).
                                 <all>
```
§ 251.7 Suspension and revocation of authorized importation programs. ( a ) FDA may suspend a SIP under any of the circumstances set forth in § 251.18, or under any other circumstances in FDA's discretion. An eligible prescription drug cannot be shipped into the United States under this part, and is subject to refusal of admission into the United States, if FDA has suspended the SIP or revoked its authorization.
( b ) SIP Sponsors and other SIP participants must agree to submit to audits of their books and records and inspections of their facilities as a condition of participation in a SIP. If a SIP Sponsor, manufacturer, Foreign Seller, Importer, qualifying laboratory, or other participant in the supply chain delays, denies, or limits an inspection, or refuses to permit entry, inspection, or audit of its facility or its records, FDA may suspend the SIP, in whole or in part, immediately.
( c ) FDA may revoke authorization of a SIP, in whole or in part, including with respect to one or more drugs in the SIP, at any time if FDA determines that: ( 1 ) The SIP Proposal contained an untrue statement of material fact;
( 2 ) The SIP Proposal omitted material information;
( 3 ) The SIP no longer meets the requirements of section 804 of the Federal Food, Drug, and Cosmetic Act, this part, or the SIP, including, among other things, if FDA finds that the manufacturer, the Foreign Seller, the Importer, or any other supply chain participant is found to be not compliant with section 501(a)(2)(A) or (B) of the Federal Food, Drug, and Cosmetic Act;
( 4 ) Continued implementation of the SIP is reasonably likely to pose additional risk to the public's health and safety;
( 5 ) Confidential manufacturer information was disclosed in violation of § 251.16;
( 6 ) Continued implementation of the SIP is not reasonably likely to result in a significant reduction in the cost of the drugs covered by the SIP to the American consumer;
( 7 ) Continued monitoring of the SIP imposes too much of a burden on FDA or HHS resources for carrying out this part or is inconsistent with FDA or HHS prioritization of resources;
( 8 ) Continued implementation of the SIP is otherwise inappropriate; or
( 9 ) Grounds exist for suspension under paragraph (a) or (b) of this section and FDA determines it should revoke, either instead of, or after, suspension.
_______________________________________ __ Michigan Supreme Court 

# Order

Lansing, Michigan



### March 26, 2007 Clifford W. Taylor, Chief Justice


### 132830 Michael F. Cavanagh Elizabeth A. Weaver Marilyn Kelly Maura D. Corrigan 

### CAROLYN SUE LOVELACE, Plaintiff-Appellant, Robert P. Young, Jr. Stephen J. Markman, Justices



### v SC: 132830 COA: 269776 Oscoda CC: 04-003853-NO GARLAND GOLF COURSE, Defendant-Appellee.

________________ _______________ __________/

On order of the Court, the application fo r leave to appeal the November 16, 2006 judgment of the Court of Appeals is consid ered, and it is DENIED, because we are not persuaded that the questions presented should be reviewed by this Court.

t0319 I, Corbin R. Davis, Clerk of the Mi chigan Supreme Cour t, certify that the foregoing is a true and complete copy of the order entered at the direction of the Court.

March 26, 2007

Clerk
§ 584.700 Hydrophobic silicas. ( a ) *Product.* Amorphous fumed hydrophobic silica or precipitated hydrophobic silica (CAS Reg. No. 68611-0944-099, silane, dichlorodimethyl-, reaction products with silica).
( b ) *Conditions of use.* An anticaking/free-flow agent in vitamin preparations for animal feed.
( c ) *Limitations.* Not to exceed 5 percent in the vitamin preparation. It shall be used in accordance with good manufacturing or feeding practices. It must be of purity suitable for intended use, and it must comply with the following specifications: ( i ) Amorphous fumed hydrophobic silica: Not less than 99.0 percent silicon dioxide after ignition. Not more than 3 ppm arsenic. Not more than 0.003 percent heavy metals (as lead). Not more than 10 ppm lead. Not more than 2.5 percent loss on drying. Not more than 2 percent loss on ignition after drying. Not more than 1 percent insoluble substances. Not more than 50 parts per million dichlorodimethylsilane.
( ii ) Precipated hydrophobic silica: Not less than 94.0 percent silicon dioxide after ignition. Not more than 3 ppm arsenic. Not more than 0.003 percent heavy metals (as lead). Not more than 10 ppm lead. Not more than 7 percent loss on drying. Not more than 8.5 percent loss on ignition after drying. Not more than 5 percent soluble ionizable salts (as sodium sulfate). Not more than 1 percent insoluble substances. Not more than 50 parts per million dichlorodimethylsilane.
[61 FR 43453, Aug. 23, 1996]
<TABLE> <S> <C>

<ARTICLE> 5
<CURRENCY> U.S. DOLLARS
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          OCT-31-1999
<PERIOD-START>                             NOV-01-1998
<PERIOD-END>                               JAN-31-1999
<EXCHANGE-RATE>                                      1
<CASH>                                         424,048
<SECURITIES>                                         0
<RECEIVABLES>                                3,756,384
<ALLOWANCES>                                    80,000
<INVENTORY>                                  4,309,888
<CURRENT-ASSETS>                             9,071,899
<PP&E>                                       8,512,597
<DEPRECIATION>                               5,815,125
<TOTAL-ASSETS>                              12,605,889
<CURRENT-LIABILITIES>                        3,073,456
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                        434
<COMMON>                                        88,527
<OTHER-SE>                                   (616,716)
<TOTAL-LIABILITY-AND-EQUITY>                12,605,889
<SALES>                                      1,741,565
<TOTAL-REVENUES>                             2,257,456
<CGS>                                        1,575,159
<TOTAL-COSTS>                                2,256,847
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             111,192
<INCOME-PRETAX>                            (1,677,436)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (1,677,436)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (1,779,649)
<EPS-PRIMARY>                                    (.21)
<EPS-DILUTED>                                    (.21)
        

</TABLE>
<PAGE>   1

November 24, 1998                                                 EXHIBIT 16.1

Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549

Ladies and Gentlemen:

                             CellPro, Incorporated

We have read Item 4 of CellPro, Incorporated's Form 8-K/A dated November 24, 
1998 and are in agreement with the statements contained in paragraph 4(a) 
therein.

Yours very truly,


/s/ PriceWaterhouseCoopers LLP
agr-ex102_195.htm





EXHIBIT 10.2

 
 
 

[IBERDROLA USA LETTERHEAD]

 

 

 

Ramón Castresana Sánchez

Director de Recursos Humanos 

 

 

 

Sheila Duncan

1 Atlantic Quay, Glasgow G2 8SP

 

March 3rd, 2015

 

 

Dear Sheila:

 

Iberdrola USA Management Corporation (the “Employer”) is pleased to confirm our offer of employment to you as Chief Human Resources Officer of Iberdrola USA based at (TBC). 

 

Your anticipated commencement of employment with the employer under this contract is scheduled for April 1st, 2015.

 

We are offering you an exempt salary of $315,000. You will be part of the Annual Incentive Program with a bonus opportunity of 45% to 90%.

 

You will be eligible for all of the employee benefits available to Iberdrola USA Management Corporation employees, including 5 weeks’ vacation, life insurance and CIGNA medical insurance.

 

In addition, you will also be eligible for the following allowances.


	
 
	
•
	
Immigration assistance (family unit)





	
 
	
•
	
Pre-assignment trip (family unit)





	
 
	
•
	
Annual housing allowance: $42,000 (net)





	
 
	
•
	
Annual car allowance: $12,000





	
 
	
•
	
Initial and return flights business class (family unit)





	
 
	
•
	
Temporary lodging (30 days)





	
 
	
•
	
Shipping of household/personal goods: 4m3





	
 
	
•
	
Tax assistance (year 1)





	
 
	
•
	
Relocation lump sum: $10,000 (net)




 

If you wish to accept this offer, please confirm this to me within 10 working days by returning this offer letter signed by you.

 

 

Dirección de Finanzas y Recursos

Tomás Redondo, 1 28033 Madrid 

Tel 91 577 65 00 Fax 91 784 21 47 

ramon.castresana@iberdrola.es

 



In the meantime, should you require any further information, please do not hesitate to contact me.

 

I would like to take this opportunity to wish you every success in your new role.

 

Yours sincerely, 

 

/s/Ramón Castresana

Ramón Castresana

 

 

For and on behalf of Iberdrola USA Management Corporation

 

The Company follows the “at will” principle of employment which provides you or the Company the opportunity to end the employment relationship at any time. However, should the Company choose to end the employment relationship, using the “at will” principle, notice period and pensions provisions in the ScottishPower contract of employment will apply

 

Please indicate by your signature, your acceptance of this offer:

 

 

 

 


	
/s/Sheila Duncan
	
5 March 2015

	
Sheila Duncan
	
Date